Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma
November 23rd 2023A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.
FDA Approves FoundationOne CDx for Capivasertib Combo in Breast Cancer
November 21st 2023Companion diagnostic designation for FoundationOne CDx may improve access to treatment with capivasertib plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer harboring select alterations.
Mirvetuximab Soravtansine Yields Meaningful OS in Platinum-Resistant Ovarian Cancer
November 17th 2023Data from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a new standard of care for patients with folate receptor α–positive, platinum-resistant ovarian cancer, says Kathleen N. Moore, MD, MS.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer
November 7th 2023Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.